Update on information – breast implant associated anaplastic large cell lymphoma

The Therapeutic Goods Administration (TGA) has recently provided updated information regarding breast implant associated-anaplastic large cell lymphoma.

The TGA has been posting updated information about this condition since 2011 and this updated alert was been generated following a recent Expert Advisory Panel in view of additional generated from research performed by a Joint BIA-ALCL task force with representatives from the Australian Society of Plastic Surgeons, Australasian Society of Aesthetic Plastic Surgeons, New Zealand Association of Plastic Surgeons the Australian Breast Device Registry and the Peter MacCallum Cancer Centre.

Dr Mark Magnusson of Allure Clinic was a member of the TGA Expert Advisory Panel and is a lead investigator and spokesperson for the Joint BIA-ALCL Task Force.

#1 what is breast implant associated-anaplastic large cell lymphoma (BIA-ALCL)?

#2 BIA-ALCL is not same as breast cancer

#3 what are the symptoms of BIA-ALC?

#4 what is the risk of developing BIA-ALCL?

#5 are some women more at risk than others?

#6 how is BIA-ALCL diagnosed?

#7 should women with breast implants be screened for BIA-ALCL?

#8 what is the treatment of BIA-ALCL?

#9 should breast implants be removed just in case?

#10 do we know what causes BIA-ALCL?

#11 are there ways to make breast implant surgery safer?

#12 what should you do if you are concerned about your breast implants?

#13 can new breast implants be inserted when BIA-ALCL is treated?

#14 where can I get more information?

#15 what should I do if I am considering breast implants?